IP Library › Granted Patent US 10,314,950
Granted Patent B2
US 10,314,950 · App. 15/596,685 · Granted Jun 11, 2019

Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications

Inventors: Sarah Mayes (Austin, TX); Christine E. Schmidt (Gainesville, FL)
Assignee: Board of Regents, The University of Texas System
A61L31/041A61K31/192A61K31/195A61L31/145A61L31/148A61L31/16A61L2300/414A61L2300/43A61L2300/62
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,314,950
App. No.
15/596,685
Granted
Jun 11, 2019
Kind
B2
Abstract

A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.

Claims (68)

1. Articles of manufacture comprising:

a first hydrogel film;

a second hydrogel film;

wherein the first hydrogel film: (a) is translucent, desiccated, amorphous, non-synthetic, and non-cytotoxic, (b) includes alginate that is negatively charged and crosslinked with at least one cation; (c) includes a first concentration of hyaluronic acid, (d) includes a first matrix that encapsulates a drug, and (e) includes layers that each include the alginate and which are fused to each other;

wherein the second hydrogel film: (a) is translucent, desiccated, amorphous, non-synthetic, and non-cytotoxic, (b) includes alginate that is negatively charged and crosslinked with the at least one cation; (c) includes a second concentration of hyaluronic acid, (d) includes a second matrix that encapsulates the drug, and (e) includes layers that each include the alginate and which are fused to each other;

wherein: (a) the first concentration of hyaluronic acid is greater than the second concentration of hyaluronic acid, and (b) the second hydrogel film is configured to degrade faster than the first hydrogel film, when implanted in a patient, in response to the first concentration of hyaluronic acid being greater than the second concentration of hyaluronic acid.

2. The articles of manufacture of claim 1 wherein the at least one cation includes calcium.

3. The articles of manufacture of claim 1 wherein:

the first hydrogel film is no less than 1% hyaluronic acid by dry weight and no greater than 33% hyaluronic acid by dry weight;

the second hydrogel film is no less than 1% hyaluronic acid by dry weight and no greater than 33% hyaluronic acid by dry weight.

4. The articles of manufacture of claim 3 wherein:

the first hydrogel film is bonded to a first surface coating, the first surface coating comprising ester bonds and at least one biopolymer selected from the group consisting of collagen, chitosan, or gelatin;

the second hydrogel film is bonded to a second surface coating, the second surface coating comprising ester bonds and at least one biopolymer selected from the group consisting of collagen, chitosan, or gelatin.

5. The articles of manufacture of claim 3 wherein;

the hyaluronic acid of the first hydrogel film and the alginate of the first hydrogel film are both formed around a first pore network;

the hyaluronic acid of the second hydrogel film and the alginate of the second hydrogel film are both formed around a second pore network.

6. The articles of manufacture of claim 3 wherein:

the first hydrogel film is unpatterned; and

the second hydrogel film is unpatterned.

7. The articles of manufacture of claim 3 wherein:

a surface of the first hydrogel film is anti-adhesive and non-attractive to cells; and

a surface of the second hydrogel film is anti-adhesive and non-attractive to cells.

8. The articles of manufacture of claim 7 wherein:

at least one of the layers of the first hydrogel film is adhesive to cells and another of the layers of the first hydrogel film includes the surface of the first hydrogel film that is anti-adhesive and non-attractive to cells;

at least one of the layers of the second hydrogel film is adhesive to cells and another of the layers of the second hydrogel film includes the surface of the second hydrogel film that is anti-adhesive and non-attractive to cells.

9. Articles of manufacture comprising:

a first hydrogel film;

a second hydrogel film;

wherein the first hydrogel film: (a) is translucent and non-synthetic, (b) includes alginate that is negatively charged and crosslinked; (c) includes a first concentration of hyaluronic acid, (d) encapsulates at least one of a drug, growth factor, hormone, protein, or combinations thereof, and (e) includes layers that each include the alginate and which are fused to each other;

wherein the second hydrogel film: (a) is translucent and non-synthetic, (b) includes alginate that is negatively charged and crosslinked; (c) includes a second concentration of hyaluronic acid, (d) encapsulates the at least one of the drug, growth factor, hormone, protein, or combinations thereof, and (e) includes layers that each include the alginate and which are fused to each other;

wherein: (a) the first concentration of hyaluronic acid is greater than the second concentration of hyaluronic acid, and (b) the second hydrogel film is configured to degrade faster than the first hydrogel film, when implanted in a patient, in response to the first concentration of hyaluronic acid being greater than the second concentration of hyaluronic acid.

10. The articles of manufacture of claim 9 wherein the alginate of the first hydrogel film is crosslinked with at least one cation; the alginate of the second hydrogel film is crosslinked with the at least one cation; the at least one cation includes calcium.

11. The articles of manufacture of claim 9 wherein:

the first hydrogel film is no less than 1% hyaluronic acid by dry weight and no greater than 33% hyaluronic acid by dry weight;

the second hydrogel film is no less than 1% hyaluronic acid by dry weight and no greater than 33% hyaluronic acid by dry weight.

12. The articles of manufacture of claim 11 wherein:

the first hydrogel film is bonded to a first surface coating, the first surface coating comprising ester bonds and at least one biopolymer selected from the group consisting of collagen, chitosan, or gelatin;

the second hydrogel film is bonded to a second surface coating, the second surface coating comprising ester bonds and at least one biopolymer selected from the group consisting of collagen, chitosan, or gelatin.

13. The articles of manufacture of claim 11 wherein;

the hyaluronic acid of the first hydrogel film and the alginate of the first hydrogel film are both formed around a first pore network;

the hyaluronic acid of the second hydrogel film and the alginate of the second hydrogel film are both formed around a second pore network.

14. The articles of manufacture of claim 11 wherein:

the first hydrogel film is unpatterned;

the second hydrogel film is unpatterned;

the first hydrogel film encapsulates the drug; and

the second hydrogel film encapsulates the drug.

15. The articles of manufacture of claim 11 wherein:

a surface of the first hydrogel film is anti-adhesive and non-attractive to cells; and

a surface of the second hydrogel film is anti-adhesive and non-attractive to cells.

16. The articles of manufacture of claim 15 wherein:

at least one of the layers of the first hydrogel film is adhesive to cells and another of the layers of the first hydrogel film includes the surface of the first hydrogel film that is anti-adhesive and non-attractive to cells;

at least one of the layers of the second hydrogel film is adhesive to cells and another of the layers of the second hydrogel film includes the surface of the second hydrogel film that is anti-adhesive and non-attractive to cells.

17. Articles of manufacture comprising:

a first hydrogel film;

a second hydrogel film;

wherein the first hydrogel film: (a) is translucent and non-synthetic, (b) includes alginate that is negatively charged and crosslinked with at least one cation; (c) includes a first concentration of hyaluronic acid, (d) includes a first matrix that encapsulates a drug, and (e) includes layers that each include the alginate and which are fused to each other;

wherein the second hydrogel film: (a) is translucent and non-synthetic, (b) includes alginate that is negatively charged and crosslinked with the at least one cation; (c) includes a second concentration of hyaluronic acid, (d) includes a second matrix that encapsulates the drug, and (e) includes layers that each include the alginate and which are fused to each other;

wherein: (a) the first concentration of hyaluronic acid is greater than the second concentration of hyaluronic acid, and (b) the second hydrogel film is configured to degrade faster than the first hydrogel film, when implanted in a patient, in response to the first concentration of hyaluronic acid being greater than the second concentration of hyaluronic acid.

18. The articles of manufacture of claim 17 wherein:

the first hydrogel film is no less than 1% hyaluronic acid by dry weight and no greater than 33% hyaluronic acid by dry weight;

the second hydrogel film is no less than 1% hyaluronic acid by dry weight and no greater than 33% hyaluronic acid by dry weight.

19. The articles of manufacture of claim 1 wherein:

the second hydrogel film is configured to release the hyaluronic acid faster than the first hydrogel film, when implanted in the patient, in response to the first concentration of hyaluronic acid being greater than the second concentration of hyaluronic acid; the first and second hydrogel films are not coupled to each other.

20. The articles of manufacture of claim 9 wherein:

the second hydrogel film is configured to release the hyaluronic acid faster than the first hydrogel film, when implanted in the patient, in response to the first concentration of hyaluronic acid being greater than the second concentration of hyaluronic acid; the first and second hydrogel films are not coupled to each other.

21. The articles of manufacture of claim 17 wherein:

the second hydrogel film is configured to release the hyaluronic acid faster than the first hydrogel film, when implanted in the patient, in response to the first concentration of hyaluronic acid being greater than the second concentration of hyaluronic acid;

the first and second hydrogel films are not coupled to each other.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 20, 2017
From: UNIVERSITY OF TEXAS, AUSTIN
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 042915/0708 →
Continuity (4)
Continuation 14803258 · Jul 20, 2015
Continuation 13269344 · Oct 7, 2011
Provisional Application 61391299 · Oct 8, 2010
Related Publication 20170312397A1 · Nov 2, 2017
Cited By (1)
US 12,697,419